Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Change in Accured Expenses (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Change in Accured Expenses for 3 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 72.0% to $12.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.4 million, a 80.61% increase, with the full-year FY2025 number at $12.4 million, up 80.61% from a year prior.
  • Change in Accured Expenses was $12.6 million for Q4 2025 at Nuvation Bio, up from $8.6 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $12.6 million in Q4 2025 to a low of -$8.9 million in Q1 2025.
  • A 3-year average of $1.6 million and a median of $1.3 million in 2023 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 455.38% in 2024, then tumbled 692.12% in 2025.
  • Nuvation Bio's Change in Accured Expenses stood at -$2.1 million in 2023, then surged by 455.38% to $7.3 million in 2024, then surged by 72.0% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Change in Accured Expenses are $12.6 million (Q4 2025), $8.6 million (Q3 2025), and $106000.0 (Q2 2025).